Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast Cancer

Douglas Yee, MD
Published: Monday, Jul 30, 2018



Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer (TNBC).

Adjuvant chemotherapy has proven to be effective for patients with TNBC, but Yee argues it is better to more effective in the neoadjuvant setting. There are very few patients, if any, who are at a low-enough risk to not require any therapy. The nature of the disease, Yee says, means there is nothing to target when it comes to treatment. Conventional chemotherapy remains the only viable option, and most, if not all, patients require therapy.


Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer (TNBC).

Adjuvant chemotherapy has proven to be effective for patients with TNBC, but Yee argues it is better to more effective in the neoadjuvant setting. There are very few patients, if any, who are at a low-enough risk to not require any therapy. The nature of the disease, Yee says, means there is nothing to target when it comes to treatment. Conventional chemotherapy remains the only viable option, and most, if not all, patients require therapy.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x